Targeted therapy blocking IL‐36 receptor signalling has been demonstrated to be a safe and effective treatment option for GPP,13 with a high proportion of patients with an IL36RN mutation demonstrating complete pustule clearance and clear/almost clear skin.32 This evidence concerns the gene IL36RN and psoriasis 14, pustular.